Medline Inc. Class A Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Medline Inc. Class A Common Stock trades at $36.04 (market cap $31.36B), while State Street SPDR S&P Biotech ETF trades at $153.21 (market cap $10.11B). The key difference: Medline Inc. Class A Common Stock is far larger — about 3.1× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Medline Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medline Inc. Class A Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| MDLN | XBI | |
|---|---|---|
Market Cap | $31.36B | $10.11B |
Volume | 10,191,251 | 12,903,266 |
Sector | Health | Broad Market / Factor |
52-Week High | $49.99 | $169.55 |
52-Week Low | $31.64 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $41.32B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →